ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents AI-driven digital twin for simulation of aging eye
The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.
AnnMarie Hipsley, DPT, PhD, presented a transformative concept in ophthalmic innovation: the “digital twin” of the human eye, embodied in the Virtual Eye Simulation Analyzer (VESA)—a virtual, AI-driven model capable of simulating the anatomy and aging of the eye—at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California. A digital twin is a virtual representation of a physical entity, and in this case, VESA was developed over the past decade to model the full lifecycle of presbyopia.
Originally designed to explore treatment options from early to advanced stages of presbyopia, VESA creates a personalized 3D ID using topography, refractive data, and the material properties of ocular tissues. “It becomes a representation of a person’s eye,” Hipsley explained. In this study, a 52-year-old eye served as the baseline model, chosen for its biomechanical stability. Leveraging Ansys and proprietary physics-based modeling, VESA simulated changes in dioptric power, lens accommodation, and structural shifts in the sclera, lens, Bruch’s membrane, and zonular fibers.
VESA’s next step: simulation of personalized treatments tailored to specific ages and anatomical profiles. “VESA was able to calculate and spit out precision patterns for each of those stages and ages,” Hipsley said. The system’s predictive capacity opens doors to virtual IOL implantation and treatment planning, allowing innovators to “test your innovation virtually… and come up with fail-fast answers” before entering clinical trials.
With patient data stored securely on a 3D ID card, the system supports longitudinal care and privacy. “Every single patient becomes 1000 simulations of data,” Hipsley noted, positioning VESA as a future-forward tool for real-time clinical updates, predictive diagnostics, and a major step toward individualized, minimally invasive ophthalmic care.
Explore More Articles
Laser scleral microporation: Unique method to treat presbyopia goes back to basics
Laser scleral microporation is a unique therapeutic solution for presbyopia that goes back to basics, rejuvenating the eye and restoring the natural dynamic mechanism of accommodation and disaccommodation. “Nature frequently develops dynamic processes, which work well for most individuals for the first 40 or 50 years of life but then, because of changes in the intrinsic …
read moreAce Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read moreLaser scleral microporation has high satisfaction in emmetropic presbyopes
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses 18-month study outcomes of laser scleral microporation in emmetropic presbyopes. “Our studies show that the patients have high patient satisfaction with laser scleral microporation treatment,” he said. “It is safe and effective, and it has great potential for this segment of …
read more